deltatrials
Recruiting OBSERVATIONAL NCT07022457

UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM)

UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM): A Prospective Observational Real-world App-based Study to Explore HRQoL Outcomes, of Adults With Metastatic Cutaneous BRAF V600 Mutation-positive Melanoma, Initiated on Combination Encorafenib and Binimetinib Therapy in the UK

Sponsor: Pierre Fabre Ltd

Conditions Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions Encorafenib + Binimetinib
Updated 2 times since 2025 Last updated: Jul 30, 2025 Started: Jul 31, 2025 Primary completion: Jan 13, 2028 Completion: Jan 13, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Metastatic Melanoma, BRAF V600 Mutation Positive and is currently actively recruiting participants. Pierre Fabre Ltd leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2025 – present · 11 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting

    Status: Not Yet Recruiting → Recruiting

  2. Jul 2025 — Sep 2025 [monthly]

    Not Yet Recruiting

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pierre Fabre Ltd
  • Vitaccess Ltd
Data source: Pierre Fabre Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations